BIOLASE INC Stock Price, News & Analysis

BIOLASE, Inc. (NASDAQ: BIOL) has regained compliance with NASDAQ's minimum bid price requirement, confirming its closing bid price has been at least $1.00 for ten consecutive days as of February 3, 2021. This follows a prior notification from NASDAQ in December 2019 regarding a price drop. Consequently, the company has canceled its Special Meeting of Stockholders scheduled for February 16, 2021, and will not pursue a reverse stock split at this time. BIOLASE specializes in developing laser systems for dental and medical applications.

BIOLASE, Inc. (NASDAQ: BIOL) urges stockholders to vote for a proposed 1-for-25 reverse stock split at the reconvened special meeting on February 16, 2021. Insufficient votes were recorded at the initial meeting held on January 22, 2021. The record date for eligible voters changed to January 25, 2021. Stockholders can vote online or by phone to ensure representation. BIOLASE, a leader in dental lasers, has sold over 41,200 laser systems globally, enhancing patient care in dentistry and medicine.

BIOLASE, Inc. (NASDAQ: BIOL) has announced preliminary revenue results for Q4 2020, estimating revenues between $8.2 million and $8.5 million, reflecting a sequential growth of 26-31%. The company reported a cash position of approximately $25 million to support its growth strategy. Notably, 78% of sales came from new users, and U.S. revenue surpassed the previous year's fourth quarter, despite challenges posed by COVID-19. BIOLASE launched initiatives like the Waterlase Endo Academy to enhance its market presence.

On January 12, 2021, BIOLASE announced a partnership with Dental Care Alliance (DCA) to enhance laser adoption in dental practices across the U.S. DCA, a major dental support organization with over 330 affiliated offices, will implement BIOLASE's EpicX and Epic Hygiene lasers, aimed at improving patient care and safety. With more than 100 systems already sold to DCA this year, BIOLASE anticipates widespread deployment throughout 2021. This agreement highlights the growing demand for advanced dental technologies that provide less invasive treatment options.

BIOLASE, Inc. (NASDAQ: BIOL) announced that Todd Norbe and John Beaver will provide an overview of the company at the H.C. Wainwright BIOCONNECT 2021 Investor Conference from January 11-14, 2021. A recorded presentation will be available on-demand starting January 11 at 6:00 a.m. ET on BIOLASE's website. Investors can also arrange virtual one-on-one meetings during the event. BIOLASE is a leader in dental lasers, with over 41,200 systems sold globally, offering innovative laser solutions for various dental procedures.

BIOLASE, a leader in dental lasers, announced a collaboration with BMW Performance Center West for the 2021 Waterlase Exclusive Trial Program. Dentists can participate in a special two-day training and use the Waterlase dental laser at no cost for 45 days. This initiative includes a chance for dentists to win a BMW vehicle lease. The promotional program aims to engage dentists by merging cutting-edge dental technology with a premium driving experience. The event series begins in January 2021.

BIOLASE (NASDAQ: BIOL) will present at the 13th annual LD Micro Main Event investor conference on December 14, 2020, at 9:40 AM PST / 12:40 PM EST. The presentation will be led by President and CEO Todd Norbe and Executive Vice President, CFO and COO John Beaver. This year's conference features a unique format with 10-minute presentations followed by Q&A sessions. This event aims to engage both executives and investors globally.

To learn more, view BIOLASE's profile.

BIOLASE announced the launch of the Waterlase Endo Academy on Nov. 14, 2020, aimed at improving patient outcomes and profitability among endodontists through advanced technology. The academy offers a community for peer-led learning and sharing best practices, featuring mentorship, online meetings, and in-person training. The Waterlase dental laser technology enhances efficiency and patient care, allowing for various dental procedures. BIOLASE has sold over 41,200 laser systems worldwide, underscoring its leadership in dental lasers.

BIOLASE, Inc. (NASDAQ: BIOL), a leader in dental lasers, will take part in the Benchmark Company Discovery One on One Investor Conference on November 18, 2020. CEO Todd Norbe and CFO John Beaver will engage in virtual meetings with institutional investors. This event highlights BIOLASE's strong commitment to advancing dental and medical laser technologies, evidenced by their proprietary systems featuring 259 patented and 41 patent-pending technologies. To date, BIOLASE has sold over 41,500 lasers across more than 80 countries, focusing on delivering superior outcomes with less pain for patients.